Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126560441 | 12656044 | 1 | I | 20160606 | 20160816 | 20160816 | PER | US-ROCHE-1771549 | ROCHE | 0.00 | M | Y | 0.00000 | 20160816 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126560441 | 12656044 | 1 | PS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Subcutaneous | 103964 | 120 | UG | /wk | ||||||||
| 126560441 | 12656044 | 2 | SS | RIBAVIRIN. | RIBAVIRIN | 1 | Oral | 21511 | 400 | MG | TABLET | BID | |||||||
| 126560441 | 12656044 | 3 | SS | SOVALDI | SOFOSBUVIR | 1 | Oral | 0 | 400 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126560441 | 12656044 | 1 | Hepatitis C |
| 126560441 | 12656044 | 2 | Hepatitis C |
| 126560441 | 12656044 | 3 | Hepatitis C |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126560441 | 12656044 | Influenza like illness | |
| 126560441 | 12656044 | Pruritus |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126560441 | 12656044 | 1 | 20160510 | 0 | ||
| 126560441 | 12656044 | 2 | 20160510 | 0 | ||
| 126560441 | 12656044 | 3 | 20160510 | 0 |